2024-12-20  8:04:27 AM Chg. -0.380 Volume Bid10:00:02 PM Ask10:00:02 PM Market Capitalization Dividend Y. P/E Ratio
72.580EUR -0.52% 0
Turnover: 0.000
-Bid Size: - -Ask Size: - 29.98 bill.EUR - -

Business description

Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.
 

Management board & Supervisory board

CEO
Kevin Sayer
Management board
Jereme Sylvain, Andrew K. Balo, Barry Regan, Chad Patterson, Don Abbey, Jake Leach, Paul Flynn, Sadie Stern, Shelly Selvaraj, Steven R. Pacelli, Sumi Shrishrimal
Supervisory board
Kevin Sayer, Barbara E. Kahn, Bridgette Heller, Eric J. Topol, M.D., Jay Skyler, M.D., Karen Dahut, Kyle Malady, Mark Foletta, Nick Augustinos, Richard Collins, Steven R. Altman
 

Company data

Name: Dexcom Inc.
Address: 6340 Sequence Drive,San Diego, CA 92121, USA
Phone: +1-858-200-0200
Fax: -
E-mail: -
Internet: https://www.dexcom.com/
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12-31
Free Float: -
IPO date: -

Investor relations

Name: Steve Pacelli
IR phone: -
IR Fax: -
IR e-mail: spacelli@dexcom.com

Main Shareholders

Others
 
53.29%
Vanguard Group
 
11.18%
BlackRock Inc.
 
8.22%
Goldman Sachs Group Inc.
 
4.87%
BAILLIE GIFFORD CO
 
4.15%
State Street Corporation
 
4.07%
CAPITAL RESEARCH GLOBAL INVESTOR
 
3.84%
SANDS CAPITAL MANAGEMENT LLC
 
3.78%
Capital World Investors
 
2.33%
Others
 
4.27%